Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis

The New England Journal of Medicine
Robert J FoxNN102/SPRINT-MS Trial Investigators

Abstract

There are limited treatments for progressive multiple sclerosis. Ibudilast inhibits several cyclic nucleotide phosphodiesterases, macrophage migration inhibitory factor, and toll-like receptor 4 and can cross the blood-brain barrier, with potential salutary effects in progressive multiple sclerosis. We enrolled patients with primary or secondary progressive multiple sclerosis in a phase 2 randomized trial of oral ibudilast (≤100 mg daily) or placebo for 96 weeks. The primary efficacy end point was the rate of brain atrophy, as measured by the brain parenchymal fraction (brain size relative to the volume of the outer surface contour of the brain). Major secondary end points included the change in the pyramidal tracts on diffusion tensor imaging, the magnetization transfer ratio in normal-appearing brain tissue, the thickness of the retinal nerve-fiber layer, and cortical atrophy, all measures of tissue damage in multiple sclerosis. Of 255 patients who underwent randomization, 129 were assigned to ibudilast and 126 to placebo. A total of 53% of the patients in the ibudilast group and 52% of those in the placebo group had primary progressive disease; the others had secondary progressive disease. The rate of change in the brain par...Continue Reading

References

Apr 26, 2001·Multiple Sclerosis : Clinical and Laboratory Research·N D RichertJ A Frank
Feb 9, 2005·Neurology·T DuningS Knecht
Jul 23, 2008·Journal of Leukocyte Biology·Asa AnderssonRobert A Harris
Jul 29, 2008·Annals of Neurology·Elizabeth FisherRichard A Rudick
Mar 5, 2010·Neurology·F BarkhofUNKNOWN MN166-001 Investigators
Jun 11, 2010·Proceedings of the National Academy of Sciences of the United States of America·Yoonsang ChoElias J Lolis
Aug 3, 2010·NeuroImage·Kunio NakamuraElizabeth Fisher
Oct 16, 2010·AJNR. American Journal of Neuroradiology·R J FoxM D Phillips
Mar 10, 2011·Annals of Neurology·Chris H PolmanJerry S Wolinsky
Oct 22, 2013·JAMA : the Journal of the American Medical Association·UNKNOWN World Medical Association
Mar 20, 2015·Multiple Sclerosis and Related Disorders·John F Kurtzke
Dec 22, 2016·The New England Journal of Medicine·Xavier MontalbanUNKNOWN ORATORIO Clinical Investigators
Oct 19, 2017·Multiple Sclerosis : Clinical and Laboratory Research·Marcello MocciaFrederik Barkhof

❮ Previous
Next ❯

Citations

Dec 28, 2018·Expert Review of Neurotherapeutics·Frederike C OertelFriedemann Paul
Apr 16, 2019·Clinical Pharmacology and Therapeutics·Ingolf Cascorbi
Aug 16, 2019·Expert Opinion on Therapeutic Targets·Joshua B BilsborrowRichard Bucala
Jun 20, 2019·Expert Review of Neurotherapeutics·Laura E BaldassariJeffrey A Cohen
Jan 16, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Maria Cristina PetraliaMaria Sofia Basile
Apr 18, 2020·Expert Opinion on Investigational Drugs·Pablo Villoslada, Lawrence Steinman
Apr 7, 2020·Current Opinion in Neurology·Per Soelberg SorensenGiancarlo Comi
Oct 11, 2019·Therapeutic Advances in Neurological Disorders·Simon Faissner, Ralf Gold
Mar 1, 2019·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Hee Kyung KimRichard Bucala
Aug 4, 2020·PloS One·Eduardo CaverzasiAri J Green
Aug 21, 2020·Medicinal Research Reviews·Michail S KukharskyVladimir L Buchman
Oct 12, 2018·Multiple Sclerosis : Clinical and Laboratory Research·Elizabeth A MillsYang Mao-Draayer
Apr 23, 2019·Stroke; a Journal of Cerebral Circulation·Annick WyssDavid Alexander Dickie
Jun 15, 2019·Nature Reviews. Rheumatology·Insoo Kang, Richard Bucala
Jun 28, 2019·Frontiers in Immunology·Neibla Priego, Manuel Valiente
Jun 27, 2019·Multiple Sclerosis Journal - Experimental, Translational and Clinical·Jenny FengDaniel Ontaneda
Jul 6, 2019·Therapeutic Advances in Neurological Disorders·Rosa CorteseAhmed T Toosy
Mar 12, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Eugenio CavalliMaria Sofia Basile
Apr 6, 2019·Current Opinion in Neurology·Matteo PardiniMaria Pia Sormani
Aug 10, 2019·Frontiers in Immunology·Melissa SchepersTim Vanmierlo
Aug 1, 2019·Biomedicines·Gabrielle Macaron, Daniel Ontaneda
Jun 21, 2020·International Journal of Molecular Sciences·Madeline BrossEvanthia Bernitsas
Feb 26, 2020·Nature Reviews. Neurology·Jaume Sastre-GarrigaUNKNOWN MAGNIMS study group
Aug 11, 2019·Nature Reviews. Drug Discovery·Simon FaissnerV Wee Yong
Dec 11, 2019·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Keith G HeinzerlingSteven J Shoptaw
May 16, 2020·Multiple Sclerosis : Clinical and Laboratory Research·Jeffrey LambeRobert A Bermel
Jan 6, 2019·Nature Reviews. Neurology·Maria A Rocca, Massimo Filippi
Dec 13, 2019·Translational Neurodegeneration·Jeroen Van SchependomMiguel D'haeseleer
Aug 10, 2020·Scientific Reports·Irene Pulido-ValdeolivasElena H Martinez-Lapiscina
Apr 5, 2020·Tropical Medicine and Infectious Disease·Thomas Holowka, Richard Bucala
Jul 8, 2020·Proceedings of the National Academy of Sciences of the United States of America·Lien D NguyenBarbara E Ehrlich
Apr 16, 2019·Current Opinion in Neurology·Bruce A C CreeHans-Peter Hartung
Jan 14, 2021·Nature Reviews. Neurology·Declan T ChardUNKNOWN MAGNIMS Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

© 2022 Meta ULC. All rights reserved